To study concurrent chemoradiation comparing by cisplatin 20 mg/m2 5 days every four weekly versus standard 100 mg/m2 three weekly in locally advanced head and neck cancer (LAHNC) patients.

Dr. Manish Kumar Chaturvedi; Dr. Rameshwaram Sharma; Dr. Ajay singh choudhary

Volume : IX, Issue : IV, April - 2020

To study concurrent chemoradiation comparing by cisplatin 20 mg/m2 5 days every four weekly versus standard 100 mg/m2 three weekly in locally advanced head and neck cancer (LAHNC) patients.

Dr. Manish Kumar Chaturvedi, Dr. Rameshwaram Sharma, Dr. Ajay Singh Choudhary

Abstract :

Background– Due toless study in concurrent chemoradiation schedule we conducted a study concurrent chemoradiation comp� by cisplatin 20 mg/m2 5 days every four weekly versus standard 100 mg/m2 three weekly in locally advanced head and neck cancer (LAHNC) patients. Methods– Hospital based prospective study conducted at Department of Radiation Oncology, S.M.S Medical College and attached group of hospital, Jaipur, Rajasthan. Response evaluation was done after 3 months of completion of treatment based on clinical examination and contrast enhanced CT scan of head and neck findings in each patient. Biopsy or fine–needle aspiration cytology was taken from any suspicious clinical and or radiological residual tumor at primary site and or nodal area. Results– The clinical response rates obtained after 6 months of treatment follow up revealed that complete response (CR) was achieved in 25 patients (71.43%) in the Study group and 22 patients (66.67%) in the Control group. The partial response (PR) rates were 7 patients (20%) in Study group and 6 patients (18.18%) in Control group. Overall response rate (OR = CR + PR) was 91.43% in the Study group and 84.85% in the Control group. Conclusion–We conclude that 20 mg/m2 of cisplatin for 5 days every four weeks can be safely used with concurrent radiation in locally advanced HNSCC without compromising efficacy